Skip to main content

Animations

MJFF Publications

1541 - 1550 of 9140 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2022
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1073/pnas.2026610118
    Citation Count: 95
  • Summary Details
    OPEN
    Title: In situ architecture of neuronal α-Synuclein inclusions
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-021-22108-0
    Citation Count: 123
  • Summary Details
    OPEN
    Title: Incidence and Progression of Rapid Eye Movement Behavior Disorder in Early Parkinson's Disease
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mdc3.13168
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Computational medication regimen for Parkinson’s disease using reinforcement learning
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-021-88619-4
    Citation Count: 28
  • Summary Details
    OPEN
    Title: High-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells
    Journal Name: STAR Protocols
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.xpro.2021.100463
    Citation Count: 24
  • Summary Details
    OPEN
    Title: Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2021.645706
    Citation Count: 24
  • Summary Details
    OPEN
    Title: Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29164
    Citation Count: 16
  • Summary Details
    OPEN
    Title: APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2021.631145
    Citation Count: 48
  • Summary Details
    OPEN
    Title: Effects of Excess Brain-Derived Human α-Synuclein on Synaptic Vesicle Trafficking
    Journal Name: Frontiers in Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnins.2021.639414
    Citation Count: 21
  • Summary Details
    OPEN
    Title: PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data
    Journal Name: Microbiome
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40168-020-00993-9
    Citation Count: 197
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.